KR20240051145A - Kras 돌연변이 암의 치료를 위한 방법 및 조성물 - Google Patents

Kras 돌연변이 암의 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20240051145A
KR20240051145A KR1020247006944A KR20247006944A KR20240051145A KR 20240051145 A KR20240051145 A KR 20240051145A KR 1020247006944 A KR1020247006944 A KR 1020247006944A KR 20247006944 A KR20247006944 A KR 20247006944A KR 20240051145 A KR20240051145 A KR 20240051145A
Authority
KR
South Korea
Prior art keywords
kras
inhibitor
poziotinib
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247006944A
Other languages
English (en)
Korean (ko)
Inventor
존 브이. 헤이마흐
자클린 피. 로비쇼
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20240051145A publication Critical patent/KR20240051145A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247006944A 2021-07-29 2022-07-29 Kras 돌연변이 암의 치료를 위한 방법 및 조성물 Pending KR20240051145A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227237P 2021-07-29 2021-07-29
US63/227,237 2021-07-29
PCT/US2022/074317 WO2023010121A1 (en) 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer

Publications (1)

Publication Number Publication Date
KR20240051145A true KR20240051145A (ko) 2024-04-19

Family

ID=85087345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247006944A Pending KR20240051145A (ko) 2021-07-29 2022-07-29 Kras 돌연변이 암의 치료를 위한 방법 및 조성물

Country Status (7)

Country Link
US (1) US20240374597A1 (https=)
EP (1) EP4376959A4 (https=)
JP (1) JP2024527109A (https=)
KR (1) KR20240051145A (https=)
CN (1) CN118043075A (https=)
CA (1) CA3227802A1 (https=)
WO (1) WO2023010121A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121846289A (zh) * 2024-10-12 2026-04-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 包括nampt抑制剂和kras抑制剂的组合物及其用途
CN119607214B (zh) * 2025-02-17 2025-06-20 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
BR112021016149A2 (pt) * 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230028798A (ko) * 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
KR102379786B1 (ko) * 2020-08-13 2022-03-25 정부환 레일 형식 보행보조기구 방향전환장치

Also Published As

Publication number Publication date
CA3227802A1 (en) 2023-02-02
JP2024527109A (ja) 2024-07-19
US20240374597A1 (en) 2024-11-14
EP4376959A4 (en) 2025-06-11
CN118043075A (zh) 2024-05-14
EP4376959A1 (en) 2024-06-05
WO2023010121A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US20240374597A1 (en) Methods and compositions for treatment of kras mutant cancer
US11446377B2 (en) Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
KR102081567B1 (ko) 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법
US11964015B2 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
JP2020525427A (ja) 癌を処置するための方法
IL292302A (en) Use of glutamate modulating agents with immunotherapies to treat cancer
US20250281527A1 (en) Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress
US20240384350A1 (en) Methods of treating cancer with kinase inhibitors
KR20230026493A (ko) Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법
US12613238B2 (en) Diagnostic and prognostic utility of exosomes in immunotherapy
CN117460843A (zh) 用激酶抑制剂治疗癌症的方法
US20210386780A1 (en) Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy
US20210260051A1 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
US20230406949A1 (en) Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment
KR20240053651A (ko) 에프린b2 발현을 이용한 암의 진단 방법
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer
US20240108623A1 (en) Methods of treating cancer with poziotinib
WO2022155311A1 (en) Methods and systems for analysis of drug target engagement and treatment of cancer
US20220390456A1 (en) Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
NZ745264B2 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
HK1208349B (zh) 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000